Appel à projets : ReCH-MIE (2022)
Titre : Immunogenicity and reactogenicity of the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi) compared to a bivalent mRNA vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in adults previously vaccinated with at least 3 doses of COVID-19 mRNA vaccine A non-inferiority multicenter single-blinded, randomized trial
Acronyme : Coviboost 2
Discipline principale : Autre
Porteur : Odile LAUNAY
Établissement : ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (CHUR), Île-de-France
Financement total : 933615 €